Is ODTX or VKTX more profitable?

Odyssey Therapeutics' return on equity of 0.00% beat Viking Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Odyssey Therapeutics N/A N/A N/A Viking Therapeutics N/A -94.56% -82.75%

Does the media refer more to ODTX or VKTX?

In the previous week, Viking Therapeutics had 6 more articles in the media than Odyssey Therapeutics. MarketBeat recorded 8 mentions for Viking Therapeutics and 2 mentions for Odyssey Therapeutics. Viking Therapeutics' average media sentiment score of 1.02 beat Odyssey Therapeutics' score of 0.00 indicating that Viking Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Odyssey Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Viking Therapeutics 3 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Is ODTX or DNLI more profitable?

Odyssey Therapeutics' return on equity of 0.00% beat Denali Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Odyssey Therapeutics N/A N/A N/A Denali Therapeutics N/A -55.27% -44.24%

Does the media refer more to ODTX or DNLI?

In the previous week, Denali Therapeutics had 4 more articles in the media than Odyssey Therapeutics. MarketBeat recorded 6 mentions for Denali Therapeutics and 2 mentions for Odyssey Therapeutics. Denali Therapeutics' average media sentiment score of 1.36 beat Odyssey Therapeutics' score of 0.00 indicating that Denali Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Odyssey Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Denali Therapeutics 4 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is ODTX or TNGX more profitable?

Odyssey Therapeutics' return on equity of 0.00% beat Tango Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Odyssey Therapeutics N/A N/A N/A Tango Therapeutics N/A -25.75% -23.36%

Does the media favor ODTX or TNGX?

In the previous week, Tango Therapeutics had 17 more articles in the media than Odyssey Therapeutics. MarketBeat recorded 19 mentions for Tango Therapeutics and 2 mentions for Odyssey Therapeutics. Tango Therapeutics' average media sentiment score of 0.85 beat Odyssey Therapeutics' score of 0.00 indicating that Tango Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Odyssey Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Tango Therapeutics 6 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher valuation & earnings, ODTX or TLX?

Telix Pharmaceuticals has higher revenue and earnings than Odyssey Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Odyssey Therapeutics $99K 12,810.88 -$325.36M -$6.77 N/A Telix Pharmaceuticals $803.79M 4.79 -$7.12M N/A N/A

Is ODTX or TLX more profitable?

Company Net Margins Return on Equity Return on Assets Odyssey Therapeutics N/A N/A N/A Telix Pharmaceuticals N/A N/A N/A

Does the media prefer ODTX or TLX?

In the previous week, Telix Pharmaceuticals had 11 more articles in the media than Odyssey Therapeutics. MarketBeat recorded 13 mentions for Telix Pharmaceuticals and 2 mentions for Odyssey Therapeutics. Telix Pharmaceuticals' average media sentiment score of 0.48 beat Odyssey Therapeutics' score of 0.00 indicating that Telix Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Odyssey Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Telix Pharmaceuticals 3 Very Positive mention(s) 5 Positive mention(s) 1 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to LEGN or ODTX?

In the previous week, Legend Biotech had 3 more articles in the media than Odyssey Therapeutics. MarketBeat recorded 5 mentions for Legend Biotech and 2 mentions for Odyssey Therapeutics. Odyssey Therapeutics' average media sentiment score of 0.00 beat Legend Biotech's score of -0.21 indicating that Odyssey Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Legend Biotech 0 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Odyssey Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Odyssey Therapeutics (ODTX) Competitors

$26.39 +1.72 (+6.97%)

As of 04:00 PM Eastern

Compare

ODTX vs. VKTX, DNLI, TNGX, TLX, and LEGN

Should you buy Odyssey Therapeutics stock or one of its competitors? Odyssey Therapeutics's main competitors and comparable companies include Viking Therapeutics (VKTX), Denali Therapeutics (DNLI), Tango Therapeutics (TNGX), Telix Pharmaceuticals (TLX), and Legend Biotech (LEGN). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Odyssey Therapeutics compare to Viking Therapeutics?

Odyssey Therapeutics (NASDAQ:ODTX) and Viking Therapeutics (NASDAQ:VKTX) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, media sentiment, profitability, valuation, earnings, risk and dividends.

76.0% of Viking Therapeutics shares are held by institutional investors. 5.3% of Viking Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Viking Therapeutics had 6 more articles in the media than Odyssey Therapeutics. MarketBeat recorded 8 mentions for Viking Therapeutics and 2 mentions for Odyssey Therapeutics. Viking Therapeutics' average media sentiment score of 1.02 beat Odyssey Therapeutics' score of 0.00 indicating that Viking Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Odyssey Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Viking Therapeutics	3 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Odyssey Therapeutics currently has a consensus price target of $33.00, suggesting a potential upside of 25.05%. Viking Therapeutics has a consensus price target of $96.63, suggesting a potential upside of 185.11%. Given Viking Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Viking Therapeutics is more favorable than Odyssey Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Odyssey Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57
Viking Therapeutics	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.75

Odyssey Therapeutics' return on equity of 0.00% beat Viking Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Odyssey Therapeutics	N/A	N/A	N/A
Viking Therapeutics	N/A	-94.56%	-82.75%

Odyssey Therapeutics has higher revenue and earnings than Viking Therapeutics. Viking Therapeutics is trading at a lower price-to-earnings ratio than Odyssey Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Odyssey Therapeutics	$99K	12,810.88	-$325.36M	-$6.77	N/A
Viking Therapeutics	N/A	N/A	-$359.64M	-$4.66	N/A

Summary

Viking Therapeutics beats Odyssey Therapeutics on 9 of the 14 factors compared between the two stocks.

How does Odyssey Therapeutics compare to Denali Therapeutics?

Odyssey Therapeutics (NASDAQ:ODTX) and Denali Therapeutics (NASDAQ:DNLI) are both healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, analyst recommendations, valuation, profitability, media sentiment, dividends, institutional ownership and earnings.

Odyssey Therapeutics' return on equity of 0.00% beat Denali Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Odyssey Therapeutics	N/A	N/A	N/A
Denali Therapeutics	N/A	-55.27%	-44.24%

Odyssey Therapeutics has higher earnings, but lower revenue than Denali Therapeutics. Denali Therapeutics is trading at a lower price-to-earnings ratio than Odyssey Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Odyssey Therapeutics	$99K	12,810.88	-$325.36M	-$6.77	N/A
Denali Therapeutics	$330.53M	12.05	-$512.54M	-$2.84	N/A

92.9% of Denali Therapeutics shares are owned by institutional investors. 9.7% of Denali Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Odyssey Therapeutics currently has a consensus price target of $33.00, suggesting a potential upside of 25.05%. Denali Therapeutics has a consensus price target of $35.92, suggesting a potential upside of 44.13%. Given Denali Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Denali Therapeutics is more favorable than Odyssey Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Odyssey Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57
Denali Therapeutics	1 Sell rating(s)	2 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.75

In the previous week, Denali Therapeutics had 4 more articles in the media than Odyssey Therapeutics. MarketBeat recorded 6 mentions for Denali Therapeutics and 2 mentions for Odyssey Therapeutics. Denali Therapeutics' average media sentiment score of 1.36 beat Odyssey Therapeutics' score of 0.00 indicating that Denali Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Odyssey Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Denali Therapeutics	4 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Denali Therapeutics beats Odyssey Therapeutics on 9 of the 14 factors compared between the two stocks.

How does Odyssey Therapeutics compare to Tango Therapeutics?

Odyssey Therapeutics (NASDAQ:ODTX) and Tango Therapeutics (NASDAQ:TNGX) are both healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, dividends, earnings, valuation, institutional ownership, profitability, analyst recommendations and media sentiment.

79.0% of Tango Therapeutics shares are owned by institutional investors. 6.5% of Tango Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Odyssey Therapeutics' return on equity of 0.00% beat Tango Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Odyssey Therapeutics	N/A	N/A	N/A
Tango Therapeutics	N/A	-25.75%	-23.36%

In the previous week, Tango Therapeutics had 17 more articles in the media than Odyssey Therapeutics. MarketBeat recorded 19 mentions for Tango Therapeutics and 2 mentions for Odyssey Therapeutics. Tango Therapeutics' average media sentiment score of 0.85 beat Odyssey Therapeutics' score of 0.00 indicating that Tango Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Odyssey Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Tango Therapeutics	6 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Odyssey Therapeutics currently has a consensus price target of $33.00, suggesting a potential upside of 25.05%. Tango Therapeutics has a consensus price target of $43.46, suggesting a potential upside of 82.00%. Given Tango Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Tango Therapeutics is more favorable than Odyssey Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Odyssey Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57
Tango Therapeutics	1 Sell rating(s)	2 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.75

Tango Therapeutics has higher revenue and earnings than Odyssey Therapeutics. Tango Therapeutics is trading at a lower price-to-earnings ratio than Odyssey Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Odyssey Therapeutics	$99K	12,810.88	-$325.36M	-$6.77	N/A
Tango Therapeutics	$62.38M	64.55	-$101.59M	-$0.85	N/A

Summary

Tango Therapeutics beats Odyssey Therapeutics on 10 of the 14 factors compared between the two stocks.

How does Odyssey Therapeutics compare to Telix Pharmaceuticals?

Odyssey Therapeutics (NASDAQ:ODTX) and Telix Pharmaceuticals (NASDAQ:TLX) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, dividends, institutional ownership, profitability, valuation, analyst recommendations, media sentiment and risk.

Telix Pharmaceuticals has higher revenue and earnings than Odyssey Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Odyssey Therapeutics	$99K	12,810.88	-$325.36M	-$6.77	N/A
Telix Pharmaceuticals	$803.79M	4.79	-$7.12M	N/A	N/A

Odyssey Therapeutics currently has a consensus price target of $33.00, suggesting a potential upside of 25.05%. Telix Pharmaceuticals has a consensus price target of $20.40, suggesting a potential upside of 80.05%. Given Telix Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Telix Pharmaceuticals is more favorable than Odyssey Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Odyssey Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57
Telix Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.63

Company	Net Margins	Return on Equity	Return on Assets
Odyssey Therapeutics	N/A	N/A	N/A
Telix Pharmaceuticals	N/A	N/A	N/A

In the previous week, Telix Pharmaceuticals had 11 more articles in the media than Odyssey Therapeutics. MarketBeat recorded 13 mentions for Telix Pharmaceuticals and 2 mentions for Odyssey Therapeutics. Telix Pharmaceuticals' average media sentiment score of 0.48 beat Odyssey Therapeutics' score of 0.00 indicating that Telix Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Odyssey Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Telix Pharmaceuticals	3 Very Positive mention(s)	5 Positive mention(s)	1 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Telix Pharmaceuticals beats Odyssey Therapeutics on 7 of the 9 factors compared between the two stocks.

How does Odyssey Therapeutics compare to Legend Biotech?

Legend Biotech (NASDAQ:LEGN) and Odyssey Therapeutics (NASDAQ:ODTX) are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, dividends, risk, earnings, profitability, media sentiment and valuation.

70.9% of Legend Biotech shares are owned by institutional investors. 0.0% of Legend Biotech shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

In the previous week, Legend Biotech had 3 more articles in the media than Odyssey Therapeutics. MarketBeat recorded 5 mentions for Legend Biotech and 2 mentions for Odyssey Therapeutics. Odyssey Therapeutics' average media sentiment score of 0.00 beat Legend Biotech's score of -0.21 indicating that Odyssey Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Legend Biotech	0 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Odyssey Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Legend Biotech has higher revenue and earnings than Odyssey Therapeutics. Legend Biotech is trading at a lower price-to-earnings ratio than Odyssey Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Legend Biotech	$1.27B	3.19	-$296.80M	-$0.25	N/A
Odyssey Therapeutics	$99K	12,810.88	-$325.36M	-$6.77	N/A

Legend Biotech presently has a consensus target price of $52.29, indicating a potential upside of 139.62%. Odyssey Therapeutics has a consensus target price of $33.00, indicating a potential upside of 25.05%. Given Legend Biotech's higher possible upside, research analysts clearly believe Legend Biotech is more favorable than Odyssey Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Legend Biotech	1 Sell rating(s)	6 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.47
Odyssey Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

Odyssey Therapeutics has a net margin of 0.00% compared to Legend Biotech's net margin of -7.21%. Odyssey Therapeutics' return on equity of 0.00% beat Legend Biotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Legend Biotech	-7.21%	-8.71%	-5.40%
Odyssey Therapeutics	N/A	N/A	N/A

Summary

Legend Biotech beats Odyssey Therapeutics on 8 of the 15 factors compared between the two stocks.

Get Odyssey Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ODTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ODTX vs. The Competition

Export

Metric	Odyssey Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$1.27B	$3.99B	$7.28B	$12.81B
Dividend Yield	N/A	3.64%	2.54%	10.69%
P/E Ratio	-3.90	11.58	271.52	24.23
Price / Sales	12,810.88	1,370.64	631.42	91.65
Price / Cash	N/A	103.92	78.13	53.57
Price / Book	3.01	17.94	13.44	6.37
Net Income	-$325.36M	-$12.50M	$3.46B	$347.74M
7 Day Performance	27.30%	3.22%	2.24%	0.08%
1 Month Performance	44.84%	6.53%	5.14%	2.13%
1 Year Performance	N/A	59.76%	27.85%	20.64%

Odyssey Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ODTX Odyssey Therapeutics	2.7568 of 5 stars	$26.39 +7.0%	$33.00 +25.0%	N/A	$1.27B	$99K	N/A	N/A
VKTX Viking Therapeutics	3.2217 of 5 stars	$34.26 +2.9%	$97.88 +185.7%	+33.7%	$4.00B	N/A	N/A	20	Positive News Analyst Upgrade
DNLI Denali Therapeutics	3.222 of 5 stars	$24.83 +0.4%	$35.92 +44.7%	+72.0%	$3.94B	$330.53M	N/A	430	Positive News
TNGX Tango Therapeutics	2.7135 of 5 stars	$27.07 -6.7%	$42.15 +55.7%	+248.3%	$3.92B	$62.38M	N/A	90	Analyst Forecast Analyst Revision
TLX Telix Pharmaceuticals	4.5925 of 5 stars	$11.52 +8.3%	$20.40 +77.1%	+13.2%	$3.91B	$803.79M	N/A	1,184	Trending News Analyst Forecast Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ODTX) was last updated on 8/21/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Odyssey Therapeutics (ODTX) Competitors

ODTX vs. VKTX, DNLI, TNGX, TLX, and LEGN

How does Odyssey Therapeutics compare to Viking Therapeutics?

Summary

How does Odyssey Therapeutics compare to Denali Therapeutics?

Summary

How does Odyssey Therapeutics compare to Tango Therapeutics?

Summary

How does Odyssey Therapeutics compare to Telix Pharmaceuticals?

Summary

How does Odyssey Therapeutics compare to Legend Biotech?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ODTX vs. The Competition

Odyssey Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Odyssey Therapeutics (ODTX) Competitors

ODTX vs. VKTX, DNLI, TNGX, TLX, and LEGN

How does Odyssey Therapeutics compare to Viking Therapeutics?

Do insiders & institutionals hold more shares of ODTX or VKTX?

Does the media refer more to ODTX or VKTX?

Do analysts rate ODTX or VKTX?

Is ODTX or VKTX more profitable?

Which has preferable earnings & valuation, ODTX or VKTX?

Summary

How does Odyssey Therapeutics compare to Denali Therapeutics?

Is ODTX or DNLI more profitable?

Which has preferable earnings & valuation, ODTX or DNLI?

Do insiders and institutionals hold more shares of ODTX or DNLI?

Do analysts recommend ODTX or DNLI?

Does the media refer more to ODTX or DNLI?

Summary

How does Odyssey Therapeutics compare to Tango Therapeutics?

Do insiders & institutionals have more ownership in ODTX or TNGX?

Is ODTX or TNGX more profitable?

Does the media favor ODTX or TNGX?

Do analysts rate ODTX or TNGX?

Which has stronger valuation and earnings, ODTX or TNGX?

Summary

How does Odyssey Therapeutics compare to Telix Pharmaceuticals?

Which has higher valuation & earnings, ODTX or TLX?

Do analysts recommend ODTX or TLX?

Is ODTX or TLX more profitable?

Does the media prefer ODTX or TLX?

Summary

How does Odyssey Therapeutics compare to Legend Biotech?

Do insiders and institutionals believe in LEGN or ODTX?

Does the media refer more to LEGN or ODTX?

Which has better earnings & valuation, LEGN or ODTX?

Do analysts recommend LEGN or ODTX?

Is LEGN or ODTX more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ODTX vs. The Competition

Odyssey Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools